



NOV E IVY

TECH CENTER 1600/2900





Patent B

Attorney's Docket No. 001560-349

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

NOBUO TSURUOKA et al

Application No.: 09/147,947

Filed: March 24, 1999

For: NOVEL SERINE PROTEASE

Group Art Unit: 1652

Examiner: W. Moore

RECEIVED ECH CENTER IEC

TRANSMITTAL LETTER FOR MISSING PARTS OF APPLICATION

BOX: SEQUENCE

Assistant Commissioner for Patents

Washington, D.C. 20231

RECEIVED

NOV 3 1999

Sir:

TECH CENTER 1600/2900

In complete response to the Office communication concerning the Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence disclosures dated August 31, 1999, enclosed please find:

- [X] A copy of the "Sequence Listing" in computer readable form in compliance with 37 C.F.R. §§1.823(b) and 1.824.
- [X] A statement that the content of the paper and computer readable copies are the same as set forth in 37 C.F.R. §1.821(f).

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Ray Do. 44,118

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: November 1, 1999

Donna M. Meuth

Registration No. 36,607

(09/99)

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

\cdot
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):
1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of th computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
The state of the s
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
7. Other:
Applicant must provide:
-priodite made provide.
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
A statement that the content of the increase o
A statement that the content of the paper and computer readable copies are the same and, where applicable, include n new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)
1.021(g) or 1.025(b) or 1.825(d)

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For Patentin software help, call (703) 308-6856

For questions regarding compliance with these requirements, please contact: